top of page
Cancer Blog
- Dr. Robert Nagourney -
Search


The Enormous Impact of EVA/PCD Chemosensitivity Testing in Patients with Rare Cancers: Durable Benefit Provided by An Unexpected Recommendation
The drug we recommended, Pazopanib, would not normally be expected to have activity in this rare and aggressive cancer.

Dr. Robert A. Nagourney, MD
Nov 32 min read


For Colon Cancer, Functional Profiling Scores a Bullseye
Colorectal cancer afflicts over 150k Americans each year with over 52k deaths. Incidence in people under 55 is rapidly rising.

Dr. Robert A. Nagourney, MD
May 30, 20232 min read


Colon Cancer: Walt Wilson
Do your homework. Take charge of your care and don’t let anyone push you around. I took charge and I’m doing great 15 years later.

Dr. Robert A. Nagourney, MD
Mar 29, 20232 min read
bottom of page
